Cancer helps oncological surgeons operate in order to get clean the cutting blades. Phase II study with 2010 radachlorin added. Information about the Marginprobe added. Article update 10 december 2011

10 december 2011: under breast cancer operations is a new study added across the Marginprobe, a device that measurement via radio waves during an operation or the snijvalkken are clean. So similar with below information but in a different way.

29 november 2011: at the bottom of the article, I added abstract of most recent phase II study with radachlorin at a PDT treatment. The authors, including Andrei v. Reshetnickov, where the same person as from 2003, we had contact with phase III studies in Europe saying that there will be set up. See for study abstract and link to full study report at the bottom of this article.

27 november 2011: source: De Volkskrant and Science Translational Medicine

Almost ten minutes ago, from 2002 say, we have a lot of information about that could be used radachlorin fabric with PDT-photo Dynamic therapy. I then try to involve doctors in Netherlands also hereby, but without result. Also I Karen, a Dutch woman with distant metastatic breast cancer, followed until her dying. I still have images of how to Karen in Germany with Dr. radachlorin Wöppel was injected and tumor cells light up on an image window, simple to set up by a laser pen there. The documentary that I've made her (who was 90% ready) wanted none of the broadcasters broadcasting because the images were violently. I think still pity because despite all the scam and fraud made by the menaen who thought rich or even richer of the radachlorin and its radachlorin, the operation of approach with PDT was well-founded.

And now comes the startling news that the Volkskrant with oncologist surgeon Dr. Van Dam worked in the academic hospital of Groningen has found a way to detect cancer cells using fluorescent dyes. If I read the principle is exactly the same and it would not surprise me if the dye used is basically the same in terms of efficacy as the radachlorin. Here's a piece from a larger article from de Volkskrant that you can read if you click here. Underneath the abstract from Science Translationall Medicine with reference to full study report.

Detecting cancer cells with fluorescent dyes

ELLEN DE VISSER − 26/11/11, 00: 00

By letting lights, kankelcellen on removing a tumor surgeons can more accurately.

Light reveals a promising new tool in detecting cancer. Fluorescent dyes so that surgeons can highlight cancer cells the tumor tissue during surgery can closely trimming. Dutch hospitals do research into the effect of the lighting technique with some forms of cancer. The expectation is that less irradiations and heroperaties are needed.

In order to make patients tumor cells luminous, get an infusion a few hours prior to surgery with a special contrast fluid, clarifies the Dallas surgeon-oncologist Go van Dam. Thanks to a light sensitive camera that hangs just above the area to operate and is connected to a screen, he can proceed meticulously.

This week describe Japanese and American researchers in Science Translational Medicine a technique that the doctors can make possible even easier. They developed a luminous green spray that quickly affects a chemical reaction with tumor cells. In cultures and in mice works excellent and so is the open road with the operating room: the surgeon may squirt the spray in the area with cancer cells, which is already a few minutes later are clearly visible.

Van Dam thinks the spray can have an added value, for example, superficial tumors with esophageal cancer, melanomas or the aggressive form of skin cancer. But for many forms of cancer can reach all corners the color never spray where tumor cells may nest, let alone the lymph glands that may have been affected, he says.
.............
Another quote from this article:
Van Dam: ' sometimes I was a day to operate, the patient was then two weeks in intensive care and the pathologist after ten days came to me with the communication that were not clean the cutting blades. So there was tumor tissue remain seated. ' When removing breast tumors can prevent the reverse, he knows: dan is actually too much breast tissue safety, causing a breast-conserving surgery removed becomes impossible.

Along with American scientists, he developed a fluorescent dye that can bind to folic acid folate, a building material. Cancer cells have very much folic acid is needed for cell division, he explains. They develop there even a special receptor. The folate it attaches itself and the cell is repealed. If a dye that folate, originates in the cancer cell is an accumulation of luminous material. The same trick can be removed with artificial antibodies, proteins that bind to certain types of cancer.

Read the full article by clicking here

Rapid Cancer Detection by Spraying a γ-glutamyl Transpeptidase Topically – Activated Fluorescent Probe

Source: Science Translational Medicine.
Sci Transl Med23 November 2011:
Vol. 3,Issue 110,p. 110ra119
Sci. transl. med. DOI: 10.1126/3002823 scitranslmed.

Cancer Imaging

Rapid Cancer Detection by Spraying a γ-glutamyl Transpeptidase Topically – Activated Fluorescent Probe

  1. Yasuteru Urano1,2,*,
  2. Sakabe Masayo3,
  3. Nobuyuki Kōsaka4,
  4. Mikako Ogawa4,
  5. Makoto Mitsunaga4,
  6. Daisuke Asanuma1,
  7. Mako Kamiya1,
  8. Matthew R. Young
href = "http://stm.sciencemag.org/content/3/110/110ra119#aff-5"5, >
  • Nagano Tetsuo3,
  • Peter L. Choyke4 and
  • Hisataka Kobayashi4,*

    • + Author Affiliations

    1. 1Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
    2. 2Basic Research Program, Japan Science and Technology Agency, Tokyo 102-0075, Japan.
    3. 3Graduate School of Pharmaceutical Science, The University of Tokyo, Tokyo 113-0033, Japan.
    4. 4Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
    5. 5Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute–Frederick, National Institutes of Health, Frederick, MD 21702, USA.
    1. ↵*To whom correspondence should be addressed. Email: kobayash@mail.nih.gov (H.K.); uranokun@m.u-tokyo.ac.jp (Y.U.)

    Abstract

    The ability of the unaided human eye to detect small cancer foci or accurate borders between cancer and normal tissue during surgery or endoscopie is limited. Fluorescent probes are useful for enhancing visualization of small tumors but are typically limited by either high background signal or the requirement for administration hours to days before use. We synthesized a cancer-selective fluorescence imaging probe activatable with rapidly, γ-glutamyl hydroxymethyl rhodamine, green (gGlu-HMRG), with intramolecular caging for complete spirocyclic quenching. Activation occurs by rapid one-step cleavage or γ-glutamyl transpeptidase (GGT) glutamate with, which is not expressed in normal tissue, but is overexpressed on the cell membrane of various cancer cells, thus leading to complete or the fluorescence probe uncaging and dequenching. GGlu-In vitro activation of human ovarian cancer cell HMRG was evident in 11 lines tested. In vivo In mouse models of human ovarian cancer, activation or "disseminated egnet intra-peritoneal HMRG occurred within 1 min or gGlu-spraying the tumor topically, creating high signal contrast between the tumor and the background. The HMRG probe is practical for clinical application gGlu-surgical or endoscopic procedures because of its rapid during and strong activation upon contact with GGT on the surface of cancer cells.

    Citation:Y. Urano, n., m., m. Ogawa Sakabe Kōsaka, m. Asanuma Mitsunaga, d., m. Kamiya, m. r. Young, t. Nagano, p. l. Choyke, h. Kobayashi, Rapid Cancer Detection by Spraying a γ-glutamyl Transpeptidase Topically – Activated Fluorescent Probe.Sci. Transl. Med.3, 110ra119(2011).

    Safety study showed no side effects and a good tolerability or "Radachlorin" ® by patients who got a PDT treatment

    Radachlorin®: Skin cancer PDT Photosensitizer phase II clinical trials☆

    • Elena Kochneva V.

        Affiliations

      • Municipal Healthcare Facility "Chelyabinsk Municipal Clinical Hospital No. 1" Vorovskogo Street, Chelyabinsk, 454048 Russia 16
      • Tel.: + 7 3512 34 62 34.
      • ,
    • Elena v. Filonenko

        Affiliations

      • Oncologische Botkinskii P.A.Gertsen Moscow Research Institute, 125284, Russia Proyezd, Moscow Vtoroy 3
      • Tel.: + 7 495 945 88 07.
      • ,
    • Elena g. Vakulovskaya

        Affiliations

      • Russian Academy of Medical Sciences Kashirskoye Shosse N.N.Blokhin Cancer Research Center, Moscow, Russia, 24 115478
      • Tel.: + 7 495 111 82 38.
      • ,
    • Elena g. Scherbakova

        Affiliations

      • RADA-PHARMA Ltd., 35, proezd, Moscow, 111024 Perovskiy Russia
      • ,
    • Oleg v. Seliverstov

        Affiliations

      • Municipal Healthcare Facility "Chelyabinsk Municipal Clinical Hospital No. 1" Vorovskogo Street, Chelyabinsk, 454048 Russia 16
    ,
  • Nikolay a. Markichev

      Affiliations

    • Russian Healthcare Ministry State Scientific Laser Medicine Centre, 40 Studencheskaya str., Moscow, Russia 121165
    • Tel.: + 7 495 146 85 64.
    • ,
  • Andrei v. Reshetnickov, PhD

      Affiliations

    • RADA-PHARMA Ltd., 35, proezd, Moscow, 111024 Perovskiy Russia
    • RADA-PHARMA International B.V. 82, West end, Noordwijkerhout, The Netherlands 2211XR
    • Tel: + 31 71 364 20 30.
    • Corresponding Author InformationCorresponding author at: app. 313, house 1, Chicherina str., Chelyabinsk 454100, Russia. Tel.: + 7 925 509 40 31; fax: + 7 495 600 07 52.

    • published online 16 August 2010.

    Summary

    "Radachlorin"®, also known in the EU Bremachlorin, a composition of 3 axis chlorophyll derivatives in an aqueous solution a , was introduced into the Russian Pharmacopoeia. Its GMP (Good Manufacturing Practice) facility based manufacturing method was patented. Laboratory experiments and clinical phase I were performed.

    Protocols were designed for basal cell carcinoma of the skin to PDT or result in GCP (Good Clinical Practice)-randomized phase II clinical studies conformed. "Radachlorin"® solution for intravenous infusions 0.35% 10mL or 0.5 – 0.6 and 1.0 in the doses – 1.2mg/kg and a gel for topical application 0.1% 25 g in the dose of 0.1g/cm2 were 2.5 W 662nm photoactivated by semiconductor laser "LAKHTA-MILON®" (St. Petersburg, Russia) in light doses of 200, 300, 400, 600, 800 (solution) (gel) J/cm2.

    Safety study showed no side effects and a good tolerability or "Radachlorin"® by patients. There was no subdermal tissue damage after both normal skin/laser and sun light exposure. The main part (98%) of the drug was metabolized or excreted in the first 48h. Drug administration at a dose of 1.0 – 1.2mg/kg and irradiation at 3h with 662nm±3 light at a dose of 300J/cm2 (solution) and 4 PDT sessions at an interval or 1 week with 3h gel exposure, followed by 400J/cm2 light exposure (gel) were found to be the optimal treatment regimes.

    Having successfully passed clinical trials, "Radachlorin"® achieved marketing authorization in Russia in 2009 and a conditional approval in South Korea in 2008. It is a candidate for phase III clinical trials in the EC and may be commercialized as a prospective second-generation photosensitizer.

    Click here For full studyreport